[ad_1]
Text size
Pfizer and Moderna were the first to walk out the door with vaccines approved for Covid-19, but three other drugmakers are closely following and could help the United States and other countries build herd immunity faster .
Novavax is launching a trial of 30,000 people in the United States and Mexico for its vaccine, which could be approved as early as spring 2021. The
Novavax
The vaccine uses proteins to trigger an immune response after it is injected, as well as a substance derived from Chilean evergreen trees to enhance that response.
Vaccines in development from AstraZeneca and Johnson & Johnson use viral vector technology, in which a modified virus triggers an immune response.
AstraZenecaof
The drug is expected to be approved in the UK this week, and the company said its vaccine “should remain effective” on the variant first discovered in that country.
More than two million Americans have been vaccinated to date with the
Pfizer
and the Moderna drugs, which both use synthetic messenger RNA to induce the body to produce protective antibodies against the virus.
Having multiple vaccines increases the overall supply and provides options that may be more effective in different cross-sections of the population. President-elect Joe Biden also plans to help with the juice supply by invoking the Defense Production Act once he takes office in January, according to a member of his Covid-19 advisory board.
This is an excerpt from the Barron’s Daily newsletter. Subscribe here.
Write to [email protected]
[ad_2]
Source link